BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34138566)

  • 1. Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile.
    Ren C; Sun N; Liu H; Kong Y; Sun R; Qiu X; Chen J; Li Y; Zhang J; Zhou Y; Zhong H; Yin Q; Song X; Yang X; Jiang B
    J Med Chem; 2021 Jul; 64(13):9152-9165. PubMed ID: 34138566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance.
    Sun N; Ren C; Kong Y; Zhong H; Chen J; Li Y; Zhang J; Zhou Y; Qiu X; Lin H; Song X; Yang X; Jiang B
    Eur J Med Chem; 2020 May; 193():112190. PubMed ID: 32179332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a PROTAC targeting ALK with in vivo activity.
    Yan G; Zhong X; Yue L; Pu C; Shan H; Lan S; Zhou M; Hou X; Yang J; Li R
    Eur J Med Chem; 2021 Feb; 212():113150. PubMed ID: 33453602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK).
    Xie S; Sun Y; Liu Y; Li X; Li X; Zhong W; Zhan F; Zhu J; Yao H; Yang DH; Chen ZS; Xu J; Xu S
    J Med Chem; 2021 Jul; 64(13):9120-9140. PubMed ID: 34176264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).
    Kang CH; Lee DH; Lee CO; Du Ha J; Park CH; Hwang JY
    Biochem Biophys Res Commun; 2018 Oct; 505(2):542-547. PubMed ID: 30274779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
    Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
    Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib.
    Ren C; Sun N; Kong Y; Qu X; Liu H; Zhong H; Song X; Yang X; Jiang B
    Eur J Med Chem; 2021 May; 217():113335. PubMed ID: 33751979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of selective degraders of EGFR
    Zhang X; Xu F; Tong L; Zhang T; Xie H; Lu X; Ren X; Ding K
    Eur J Med Chem; 2020 Apr; 192():112199. PubMed ID: 32171162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors.
    Lei H; Fan S; Zhang H; Liu YJ; Hei YY; Zhang JJ; Zheng AQ; Xin M; Zhang SQ
    Eur J Med Chem; 2020 Jan; 186():111888. PubMed ID: 31787359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
    Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
    Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
    Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
    Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibition agents.
    Wu F; Yao H; Li W; Zhang N; Fan Y; Chan ASC; Li X; An B
    Bioorg Med Chem Lett; 2021 Sep; 48():128253. PubMed ID: 34245852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors.
    Zhou F; Zhang L; Jin Y; Liu W; Cheng P; He X; Xie J; Shen S; Lei J; Ji H; Hu Y; Liu Y; Cui Y; Lv Q; Lan J
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1257-1261. PubMed ID: 29534926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
    Huang WS; Liu S; Zou D; Thomas M; Wang Y; Zhou T; Romero J; Kohlmann A; Li F; Qi J; Cai L; Dwight TA; Xu Y; Xu R; Dodd R; Toms A; Parillon L; Lu X; Anjum R; Zhang S; Wang F; Keats J; Wardwell SD; Ning Y; Xu Q; Moran LE; Mohemmad QK; Jang HG; Clackson T; Narasimhan NI; Rivera VM; Zhu X; Dalgarno D; Shakespeare WC
    J Med Chem; 2016 May; 59(10):4948-64. PubMed ID: 27144831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
    Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
    Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer.
    Sharda S; Khandelwal R; Adhikary R; Sharma D; Majhi M; Hussain T; Nayarisseri A; Singh SK
    Curr Top Med Chem; 2019; 19(13):1129-1144. PubMed ID: 31109278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation.
    Su Z; Yang T; Wang J; Lai M; Tong L; Wumaier G; Chen Z; Li S; Li H; Xie H; Zhao Z
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127327. PubMed ID: 32631532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer.
    Liu Q; Tu G; Hu Y; Jiang Q; Liu J; Lin S; Yu Z; Li G; Wu X; Tang Y; Huang X; Xu J; Liu Y; Wu L
    Eur J Med Chem; 2022 Jan; 228():114013. PubMed ID: 34864330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.